Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 24, 2025
In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.
Journal: Acta dermato-venereologica
Published: April 11, 2025
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Journal: The Journal of allergy and clinical immunology
Published: July 26, 2024
Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation.
Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation.
Journal: The Journal of investigative dermatology
Published: May 24, 2024
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma.
Journal: Blood cancer journal
Published: May 16, 2024
Social determinants of health linked with oral health in a representative sample of U.S. adults.
Journal: BMC oral health
Published: May 16, 2024
Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides.
Journal: The Journal of investigative dermatology
Published: June 01, 2023
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Journal: The British journal of dermatology
Published: April 21, 2023
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: April 26, 2022
Central memory T cells are the most effective precursors of resident memory T cells in human skin.
Journal: Science immunology
Published: April 22, 2022
Last Updated: 09/26/2026